Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal

Abstract

This cost evaluation can support Senegal's future vaccine introductions and inform other countries planning to introduce HPV vaccine nationwide. These findings support previous costing studies which anticipated potential economies of scale during the transition from HPV vaccine pilot demonstration projects to national introduction.